According to the COVID-19 updates, Indonesia has now become the first country in the world that gives a green signal to the Novavax Covid-19 vaccine, which is Maryland-based biotech announced on Monday. This could be a possible game changer in the Covid-19 battle and a major turning point and milestone for the company which has manufactured the vaccine and managed to introduce it into the market in its 34-year history.

Key Insights

Novavax shot has a significant number of advantages over existing vaccines in the market as this vaccine could help ramp up the vaccination drives globally. Moreover, it appears to be efficient and on par with mRNA vaccines from Pfizer and Moderna likes, and unlike those vaccine shots that use protein containing a part of the coronavirus that stimulates the immune response.

Novavax contains an older technology in which most of the hesitant individuals who are resistant to the vaccine may be more comfortable. In addition, the shots can also be shipped and stored at the normal refrigerator temperature and not in the ultracold freezers that are widely used by vaccine providers. Despite the manufacturing issues, more than 1 billion doses are promised to be supplied to low and middle-income countries and also widens the chasm in vaccine access amid wealthy countries and the rest of the world.

What you should be looking for?

The chief executive of Novavax, Stanley Erck, said that “landmark moment… is the first of many authorizations that Novavax expects in the coming weeks and months for our vaccine.”

Novavax has already signed for the emergency authorization in India, along with the WHO and the Philippines. Moreover, the company also added that it is anticipating filing the emergency authorization with the US FDA by December end.

Surprising Facts

  • Being a struggling company that hasn’t brought vaccines to the market in 34-year history, the U.S. government bet big on Novavax for tackling the Covid-19 situation.
  • Operation Warp Speed- The project initiated in Trump’s administration intended to ramp up vaccine drives and production- he also invested $1.6 billion in the company.